Top ▲
GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Target not currently curated in GtoImmuPdb
Target id: 1845
Nomenclature: receptor tyrosine kinase like orphan receptor 1
Abbreviated Name: ROR1
Family: Type VIII RTKs: ROR family
Gene and Protein Information ![]() |
||||||
| Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
| Human | 1 | 937 | 1p31.3 | ROR1 | receptor tyrosine kinase like orphan receptor 1 | |
| Mouse | 1 | 937 | 4 45.71 cM | Ror1 | receptor tyrosine kinase-like orphan receptor 1 | |
| Rat | - | 937 | 5q33 | Ror1 | receptor tyrosine kinase-like orphan receptor 1 | |
Previous and Unofficial Names ![]() |
| NTRKR1 | neurotrophic tyrosine kinase, receptor-related 1 |
Database Links ![]() |
|
| Alphafold | Q01973 (Hs), Q9Z139 (Mm) |
| BRENDA | 2.7.10.1 |
| CATH/Gene3D | 2.60.40.10, 1.10.2000.10 |
| ChEMBL Target | CHEMBL4665585 (Hs), CHEMBL2176781 (Mm) |
| Ensembl Gene | ENSG00000185483 (Hs), ENSMUSG00000035305 (Mm), ENSRNOG00000029449 (Rn) |
| Entrez Gene | 4919 (Hs), 26563 (Mm), 362550 (Rn) |
| Human Protein Atlas | ENSG00000185483 (Hs) |
| KEGG Enzyme | 2.7.10.1 |
| KEGG Gene | hsa:4919 (Hs), mmu:26563 (Mm), rno:362550 (Rn) |
| OMIM | 602336 (Hs) |
| Pharos | Q01973 (Hs) |
| RefSeq Nucleotide | NM_001083592 (Hs), NM_013845 (Mm), NM_001108671 (Rn) |
| RefSeq Protein | NP_001077061 (Hs), NP_038873 (Mm), NP_001102141 (Rn) |
| UniProtKB | Q01973 (Hs), Q9Z139 (Mm) |
| Wikipedia | ROR1 (Hs) |
Enzyme Reaction ![]() |
||||
|
||||
| General Comments |
| ROR1 is overexpressed by a variety of solid and hematological cancers (e.g. a subset of non-small cell lung cancer, triple-negative breast, pancreatic , and prostate cancers, B cell chronic lymphocytic leukemia and mantle cell lymphoma) and it is being investigated as a molecular target for therapeutic potential in ROR1 positive cancers. For example, VelosBio have an anti-ROR1 antibody drug conjugate (VLS-101) in Phase 2 trial as monotherapy for ROR1 positive cancers (NCT04504916). The toxic payload delivered by VLS-101 is the microtubule disrupting cytotoxin, monomethyl auristatin E (MMAE). In November 2020 Merck bought VelosBio. Juno Therapeutics (part of Bristol Myers Squibb) are taking a different route to target ROR1, with their ROR1-targeting (CAR) T-cells in clinical trial NCT02706392. |